Simple Search Results

Didn't find what you were looking for? Try the Advanced Search »

Search Again »

Abstract Number: 857 • 2013 ACR/ARHP Annual Meeting
Impact of Urate Lowering Therapy On Renal Disease Progression in Patients With Hyperuricemia
Gerald D. Levy¹, T. Craig Cheetham², Nazia Rashid³ and Fang Niu², ¹Int Med/Rheumatology, Southern California Permanente Medical Group, Downey, CA, ²Pharmacy Analytical Services, Kaiser Permanente, Downey, CA, ³Pharmacy Analytical Services, Kaiser Permanente Southern California, Downey, CA
Background/Purpose: The relationship between elevated serum Uric Acid [sUA] and progression of chronic kidney disease is well established.1-3 There are a several small studies on…
Abstract Number: 841 • 2013 ACR/ARHP Annual Meeting
The Prevalence Of Fibromyalgia In The General Population – a Comparison Of The ACR 1990, 2010 and Modified 2010 Classification Criteria
Gareth T. Jones¹, Marcus Beasley¹, Fabiola Atzeni², Elisa Flüß¹, Piercarlo Sarzi-Puttini² and Gary Macfarlane¹, ¹Musculoskeletal Research Collaboration (Epidemiology Group), University of Aberdeen, Aberdeen, United Kingdom, ²Rheumatology Unit, L. Sacco University Hospital, Milan, Italy
Background/Purpose: In 1990 the ACR published criteria for the classification of fibromyalgia (FM), based on widespread pain and tenderness. In 2010 new criteria were published…
Abstract Number: 439 • 2013 ACR/ARHP Annual Meeting
Tofacitinib, An Oral Janus Kinase Inhibitor: Analysis Of Gastrointestinal Adverse Events Across The Rheumatoid Arthritis Clinical Program
E. B. Lee¹, J. R. Curtis², R. Riese³, C. A. Connell³, R. Chew³, M.G. Boy³, E. Maller⁴, C. Su⁴ and L. Wang³, ¹Seoul National University, Seoul, South Korea, ²Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ³Pfizer Inc, Groton, CT, ⁴Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor being investigated as a targeted immunomodulator in rheumatoid arthritis (RA). This analysis aimed to describe and…
Abstract Number: 233 • 2013 ACR/ARHP Annual Meeting
Ultrasonographic Evaluation Of Patellar Cartilage and Triangular Fibrocartilage In Patients With Familial Benign Hypercalcemia
Alberto Batticciotto¹, Diana Certan², Valentina Varisco¹, Marco Antivalle³, Fabiola Atzeni⁴, Maurizio Bevilacqua² and Piercarlo Sarzi-Puttini⁴, ¹Rheumatology, Rheumatology Unit, L. Sacco University Hospital, Milan, Italy, ²Endocrinology Unit, L. Sacco University Hospital, Milan, Italy, ³Rheumatology, L. Sacco University Hospital, Milano, Italy, ⁴Rheumatology Unit, L. Sacco University Hospital, Milan, Italy
Background/Purpose: Familial benign hypercalcemia (FBH) is a rare autosomal dominant disease that is caused by a mutation in calcium sensing receptor (CaSR) genes and characterised…
Abstract Number: 196 • 2013 ACR/ARHP Annual Meeting
Uptake Of The American College Of Rheumatology’s Rheumatology Clinical Registry: Quality Measure Summary Data
Jinoos Yazdany¹, Salahuddin Kazi², Rachel Myslinski³ and Melissa Francisco⁴, ¹Medicine, University of California, San Francisco, San Francisco, CA, ²Internal Medicine/Rheumatology, UT Southwestern Medical Center, Dallas, TX, ³Practice, Advocacy, & Quality, American College of Rheumatology, Atlanta, GA, ⁴Registries & Health Informatics, American College of Rheumatology, Atlanta, GA
Background/Purpose: The RCR provides ACR members with an infrastructure for quality reporting related to rheumatoid arthritis, gout, osteoarthritis, osteoporosis, and drug safety. Currently in its…
Abstract Number: 85 • 2013 ACR/ARHP Annual Meeting
Cartilaginous Uric Acid Deposition In Advanced Osteoarthritis: Innocent Bystander Or Promotor Of Cartilage Destruction?
Tim Bongartz¹, Andre M Oliveira², Rafael J Sierra³, Arlen D Hanssen³ and Michael J Taunton³, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Pathology, Mayo Clinic, Rochester, MN, ³Orthopedic Surgery, Mayo Clinic, Rochester, MN
Background/Purpose: Recent studies have suggested that synovial fluid uric acid could contribute to tissue inflammation, disease severity and progression of osteoarthritis (OA). Intraarticular uric acid…
Abstract Number: 87 • 2013 ACR/ARHP Annual Meeting
Global and Country Specific Burden Of Musculoskeletal Disorders:a Report From The Global Burden Of Diseases Musculoskeletal Expert Group
Lyn March¹, Damian Hoy², Emma Smith³, Rachelle Buchbinder⁴, Marita Cross³, Peter Brooks⁵, Theo Vos² and Anthony D. Woolf⁶, ¹Rheumatology, Institute of Bone and Joint Research, Kolling Institute, University of Sydney, Sydney, Australia, ²School of Population Health, University of Queensland, Brisbane, Australia, ³Rheumatology, University of Sydney, Insitute of Bone and Joint Research, Royal North Shore Hospital, St Leonards NSW, Australia, ⁴Monash Department of Clinical Epidemiology at Cabrini Hospital, Department of Epidemiology and Preventive Medicine, Monash University, Malvern, Victoria, Australia, ⁵School of Population Health, Australian Health Workforce Institute, University of Melbourne, Melbourne, Australia, ⁶Rheumatology Dept, Royal Cornwall Hospital, Truro Cornwall, United Kingdom
Background/Purpose: The first Global Burden of Diseases (GBD) Study was conducted by the World Bank and WHO during the 1990’s and ranked diseases by their…
Abstract Number: 91 • 2013 ACR/ARHP Annual Meeting
Risk Factors For Incident Hyperuricemia During Mid-Adulthood In African American and White Men and Women Enrolled In The Atherosclerosis Risk In Communities Study
Mara McAdams DeMarco¹, Andrew Law², Janet W. Maynard³, Josef Coresh¹ and Alan N. Baer⁴, ¹Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ²Epidemiology, Johns Hopkins, Baltimore, MD, ³Rheum/Mason F Lord Bldg/CtrTow, Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, ⁴Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose : Increased serum urate levels are associated with poor outcomes including but not limited to gout. Better understanding of which patients are at risk…
Abstract Number: 2065 • 2012 ACR/ARHP Annual Meeting
Uptake of the American College of Rheumatology’s (ACR) Rheumatology Clinical Registry (RCR): Quality Measure Summary Data
Salahuddin Kazi¹, Itara Barnes², Jinoos Yazdany³ and Rachel Myslinski⁴, ¹Internal Medicine/Rheumatology, UT Southwestern Medical Center, Dallas, TX, ²Quality, Registries, and Health Informatics, American College of Rheumatology, Atlanta, GA, ³Medicine, University of California, San Francisco, San Francisco, CA, ⁴Practice, Advocacy, & Quality, American College of Rheumatology, Atlanta, GA
Background: The RCR was launched by the ACR to provide members with an infrastructure for quality reporting related to rheumatoid arthritis, gout, osteoarthritis, osteoporosis, and…
Abstract Number: 1978 • 2012 ACR/ARHP Annual Meeting
A Web-Based Intervention Aimed to Improve Bone Health Among Individuals On Chronic Glucocorticoids
Amy H. Warriner¹, Ryan C. Outman², Nathan Markward³, Ronald Aubert³, Jeffrey R. Curtis⁴, Robert Epstein³, Felix Freuh³, Julia McEachern³, David T. Redden⁵, Monika M. Safford², Eric Stanek³, Amy Steinkellner³ and Kenneth G. Saag⁶, ¹Endocrinology, Diabetes, and Metabolism, The University of Alabama at Birmingham, Birmingham, AL, ²Preventive Medicine, University of Alabama at Birmingham, Birmingham, AL, ³Medco, Bethesda, MD, ⁴Rheumatology & Immunology, Univ of Alabama-Birmingham, Birmingham, AL, ⁵Biostatistics, University of Alabama at Birmingham, Birmingham, AL, ⁶Div Clinical Immun & Rheum, Univ of Alabama-Birmingham, Birmingham, AL
Background/Purpose: Despite a significant associated fracture risk, previous population-based studies document low osteoporosis treatment rates for individuals treated with chronic glucocorticoids (GCs) at risk for…
Abstract Number: 1929 • 2012 ACR/ARHP Annual Meeting
Pernicious Anemia and Vitamin B-12 Deficiency in Autoimmune Disease: Neglecting the Feet Will Lead You Astray
Michael R. Lovy, Desert Oasis Healthcare, Palm Springs, CA
Background/Purpose: The occurrence of multiple autoimmune disorders in individual patients is commonly observed. Rarely, this is explained by recently recognized genetically based autoimmune polyendocrine syndromes.…
Abstract Number: 1905 • 2012 ACR/ARHP Annual Meeting
Increase of Thyroid Stimulating Hormone in Patients On Febuxostat Treatment
Fernando Perez-Ruiz¹ and Ana M. Herrero-Beites², ¹Servicio de Reumatologia, Hospital Universitario Cruces, Baracaldo, Spain, ²Physical Medicine Division, Hospital de Gorliz, Gorliz, Spain
Background/Purpose: to evaluate whether TSH increases during febuxostat treatment and factors that could be implicated.Methods: before starting febuxostat, patients had analysis at baseline and month…
Abstract Number: 1909 • 2012 ACR/ARHP Annual Meeting
Use of Uric Lowering Therapies within a Large Health Care System
Robert A. Overman¹, Brian F. Mandell² and Chad L. Deal³, ¹Rheumatology, Cleveland Clinic Foundation, Cleveland, OH, ²Dept of Rheum/Immun NA10, The Cleveland Clinic, Cleveland, OH, ³Dept of Rheum & Imm Dis /A 50, Cleveland Clinic, Cleveland, OH
Background/Purpose: Guidelines for initiating urate lowering therapy (ULT) in the treatment of gout recommend treatment to a target serum urate (SUA) level of ≤6mg/dl with…
Abstract Number: 1847 • 2012 ACR/ARHP Annual Meeting
Status of the Rheumatology Clinical Trials Portfolio: Data From Clinicaltrials.Gov
Ankoor Shah¹, Samuel Broderick², Karen Chiswell², Asba Tasneem² and John S. Sundy², ¹Rheumatology and Immunology, Duke University Medical Center, Durham, NC, ²Duke Clinical Research Institute, Duke University Medical Center, Durham, NC
Background/Purpose: In an effort to provide a comprehensive listing of clinical trials Congress initiated the creation of the ClinicalTrials.gov (CT.gov) registry in 1997. In 2007…
Abstract Number: 1632 • 2012 ACR/ARHP Annual Meeting
Arhalofenate Is a Novel Dual-Acting Agent with Uricosuric and Anti-Inflammatory Properties
Yun-Jung Choi, Vanina Larroca, Annette Lucman, Vic Vicena, Noe Abarca, Tim Rantz, Brian E. Lavan and Charles A. McWherter, Biology, Metabolex, Inc., Hayward, CA
Background/Purpose: In most patients with gout, elevated serum urate is linked to excess uric acid reabsoprtion in the proximal renal tubule by anion transporters/exchangers, including…

Search Again »

Didn't find what you were looking for? Try the Advanced Search »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].